Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific microbial members of the microbiota is challenging, because clinically detectable inflammation and its treatment can alter the microbiota's composition. Immunologic checkpoint blockade with ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a prospective study of patients with metastatic melanoma undergoing ipilimumab treatment and correlate the pre-inflammation faecal microbiota and microbiome composition with subsequent colitis development. We demonstrate that increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved in polyamine transport and B vitamin biosynthesis is associated with an increased risk of colitis. Identification of these biomarkers may enable interventions to reduce the risk of inflammatory complications following cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In parallel to microbial therapeutics, microbial signatures are being evaluated as a novel class of biomarkers, applied for stratification of efficacy and safety in clinical trials across multiple indications (Ananthakrishnan et al., 2017; Dubin et al., 2016).”
From Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers (2021) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The capacity of the microbiome to generate polyamines has also been associated with reduced toxicity of antibody to CTLA-4 in melanoma patients (22).”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“differences may be related to several different factors – including differences in techniques used to analyze samples and reference databases used for analysis – which varied widely across the studies”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CTLA-4 blockade (alone or in combination with anti-PD-1/PD-L1) produces toxicities in a dose-dependent fashion.22,23”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, there is evidence that the microbiome is associated with development of immune-related adverse events (irAEs) following ICB7–9.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [8]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationUCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Cited by
Items 101–200 of 991
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
Yshii, L. M., Hohlfeld, R., & Liblau, R. S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.144 · Cited by 173
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
Dougan, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01547 · Cited by 170
“Fecal microbiota transplant is an investigational approach that may have promise as well, though presently very little is known about the microbial features of this syndrome (66).”
BackgroundThe Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy
Young, A., Quandt, Z., & Bluestone, J. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0487 · Cited by 169
“Similarly, enrichment of the Bacteroidetes phylum was identified in colitis-free, ipilimumabtreated melanoma patients (49, 52), whereas the Firmicutes phylum was enriched preceding ipilimumab in patients developing colitis (49).”
BackgroundZhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164
Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors
Cramer, P., & Bresalier, R. S. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0540-6 · Cited by 167
Gori, S., Inno, A., Belluomini, L., Bocus, P., Bisoffi, Z., Russo, A., & Arcaro, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.003 · Cited by 165
Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities
Pandey, H., Tang, D. W. T., Wong, S. H., & Lal, D. (2023) · Cancers · doi:10.3390/cancers15030866 · Cited by 159
Halsey, T. M., Thomas, A. S., Hayase, T., Ma, W., Abu-Sbeih, H., Sun, B., Parra, E. R., Jiang, Z.-D., DuPont, H. L., Sanchez, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4006 · Cited by 161
“Differential gut microbial signatures have been identified among ICI therapy responders versus nonresponders, as well as among those with a predisposition for developing IMC (12, 26, 27).”
BackgroundImmuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
Giannone, G., Ghisoni, E., Genta, S., Scotto, G., Tuninetti, V., Turinetto, M., & Valabrega, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124414 · Cited by 159
“A study demonstrated that the presence of bacteria belonging to the Bacteroidetes phylum in the intestinal microbiota is correlated with resistance to the development of ICI-induced colitis [148].”
BackgroundEffects of polysaccharides on glycometabolism based on gut microbiota alteration
Fang, Q., Hu, J., Nie, Q., & Nie, S. (2019) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2019.08.015 · Cited by 157
Corticosteroids and Cancer Immunotherapy
Goodman, R. S., Johnson, D. B., & Balko, J. M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3181 · Cited by 196
Gut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 194
“1 and Table 1) 44 – 89 .”
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Cho, T., & Uetrecht, J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00357 · Cited by 164
Zhu, J., Armstrong, A. J., Friedlander, T. W., Kim, W. K., Pal, S. K., George, D. J., & Zhang, T. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0314-1 · Cited by 166
“have discovered that the presence of specific microbiota phylotypes can help predict a patient’s risk of developing colitis following CTLA-4 blockade [66].”
BackgroundVernocchi, P., Gili, T., Conte, F., CHIERICO, F. D., Conta, G., Miccheli, A., Botticelli, A., Paci, P., Caldarelli, G., Nuti, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228730 · Cited by 174
“Recently, several studies suggested the role of the GM in modulating patient response to immunotherapy in cancer [16,17,36,62,63].”
BackgroundHayase, E., & Jenq, R. R. (2021) · Genome Medicine · doi:10.1186/s13073-021-00923-w · Cited by 145
“with resistance to development of ICI-associated colitis in a study of metastatic melanoma patients treated with anti-CTLA-4 antibody [59], a finding that was later reproduced by another study [8].”
ResultSfanos, K. S., Markowski, M. C., Peiffer, L. B., Ernst, S. E., White, J. R., Pienta, K. J., Antonarakis, E. S., & Ross, A. E. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0061-x · Cited by 147
“There is, however, compelling evidence that the GI microbiome is involved in multiple-related processes such as modulation of circulating hormone levels [12, 13], stimulation of antitumor immune responses [5, 6, 8], and induction of treatment-related toxicities (including immunotherapy-induced colitis [14] and radiati…”
BackgroundWang, T., Zheng, N., Luo, Q., Jiang, L., He, B., Yuan, X., & Shen, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01235 · Cited by 146
“Indeed, novel evidence supports the idea that in both anti-CTLA-4 and anti-PD-1 colitis, specific “favorable” or “unfavorable” microbiome profiles may affect the efficacy of the immune response and, consequently, the appearance of gastrointestinal irAEs (18, 19).”
BackgroundCarcinogenesis and therapeutics: the microbiota perspective
Tsilimigras, M. C. B., Fodor, A., & Jobin, C. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.8 · Cited by 144
Role of the microbiota in response to and recovery from cancer therapy
Blake, S. J., Wolf, Y., Boursi, B., & Lynn, D. J. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00951-0 · Cited by 158
“…of the Enterococcus peptidoglycan biosynthesis pathway is positively correlated with complete CAR T cell responses 12 11–13 , immune checkpoint blockade (ICB) 6,10,18,21,54,107–110,120,132,133 , immune-agonist antibodies (IAAs) 19 , haematopoietic cell transplantation (HCT) 20,83,85–87, 185 ,”
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies
Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.120.315894 · Cited by 138
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Zhang, M., Liu, J., & Xia, Q. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00442-x · Cited by 167
“As for the functional components of gut microbiome, two pathways (polyamine transport system and biosynthesis of B vitamins) were found related to colitis-free patients with melanoma [45].”
BackgroundInfluentialMicrobial markers in colorectal cancer detection and/or prognosis
Villéger, R., Lopès, A., Véziant, J., Gagnière, J., Barnich, N., Billard, E., Boucher, D., & Bonnet, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i22.2327 · Cited by 158
Colorectal cancer and gut microbiota studies in China
Wang, Z., Dan, W., Zhang, N., Fang, J., & Yang, Y. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2236364 · Cited by 170
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
Tang, L., Wang, J., Lin, N., Zhou, Y., He, W., Liu, J., & Ma, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.800879 · Cited by 144
“Fragilis increase is considered to be the protective factor of CIC (81, 108).”
BackgroundClinical assessment of immune-related adverse events
Sosa, A. E., Cadena, E. L., Olivé, C. S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918764628 · Cited by 146
Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy
Qiu, Q., Lin, Y., Ma, Y., Li, X., Liang, J. B., Chen, Z., Liu, K., Huang, Y., Luo, H., Huang, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612202 · Cited by 151
Dynamic Distribution of Gut Microbiota in Goats at Different Ages and Health States
Wang, Y., Zhang, H., Zhu, L. F., Xu, Y., Liu, N., Sun, X., Hu, L., Huang, H., Wei, K., & Zhu, R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02509 · Cited by 147
“Rikenellaceae are correlated with resistance to the development of colitis following CTLA-4 blockade and can limit inflammation by stimulating T-regulatory cell differentiation (Dubin et al., 2016).”
BackgroundConsiderations for designing preclinical cancer immune nanomedicine studies
Jiang, W., Wang, Y., Wargo, J. A., Lang, F. F., & Kim, B. Y. S. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-00817-9 · Cited by 142
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 145
“and of colitis in patients with melanoma (74, 75).”
BackgroundInfluentialBiomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
Hommes, J. W., Verheijden, R. J., Suijkerbuijk, K. P. M., & Hamann, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.585311 · Cited by 139
Gowen, M. F., Giles, K. M., Simpson, D., Tchack, J., Zhou, H., Moran, U., Dawood, Z., Pavlick, A. C., Hu, S., Wilson, M. A., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1452-4 · Cited by 132
“More recently, in a small study, the baseline microbiome composition of melanoma patients was found to be associated with onset of immune mediated colitis following anti-CTLA-4 treatment [15]; while this finding demonstrates the potential utility of pretreatment/baseline biomarkers of toxicity development, it does not…”
Harnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
Autoimmune complications of immunotherapy: pathophysiology and management
Chan, K. K., & Bass, A. R. (2020) · BMJ · doi:10.1136/bmj.m736 · Cited by 140
Dimitriou, F., Hogan, S. A., Menzies, A. M., Dummer, R., & Long, G. V. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.031 · Cited by 133
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 131
“In another study, researchers identified Bacteroides species as a protective factor against the development of enterocolitis (230).”
BackgroundTargeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs
Feng, W., Liu, J., Ao, H., Yue, S., & Peng, C. (2020) · Theranostics · doi:10.7150/thno.47289 · Cited by 121
“found out that a higher abundance of Bacteroidetes is correlated with ipilimumab-induced colitis in humans [133].”
BackgroundReview: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Suarez-Almazor, M. E., Kim, S. T., Abdel‐Wahab, N., & Diab, A. K. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40043 · Cited by 131
“colitis, and that increased representation of Bacteroides phylum was associated with lower odds of developing colitis (55).”
Backgroundvon Itzstein, M. S., Khan, S., & Gerber, D. E. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa081 · Cited by 127
“Metabolic products of the fecal microbiome including a polyamine transport system, and synthesis of thiamine, riboflavin, and pantothenate were computed in a machine learning algorithm that predicted development of anti-CTLA-4 colitis with sensitivity of 70% and specificity of 100% (59).”
BackgroundMethodInfluentialCosta, D. A., Nobre, J. G., Batista, M. V., Ribeiro, C., Callé, C., Cortés, A., Marhold, M., Negreiros, I., Borralho, P., Brito, M., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.584332 · Cited by 140
“In addition, if vancomycin was administered to mice with colitis and treated with anti-CTLA-4, they had more severe manifestation of intestinal disease, while administration of a common probiotic with Bifidobacterium could alleviate symptoms, without a detrimental effect on antitumour immunity (Dubin et al., 2016; Pan…”
BackgroundChamseddine, A. N., Ducreux, M. P., Armand, J., Paolettí, X., Satar, T., Paci, A., & Mir, O. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.002 · Cited by 124
Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?
Villéger, R., Lopès, A., Carrier, G., Véziant, J., Billard, E., Barnich, N., Gagnière, J., Vazeille, E., & Bonnet, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184584 · Cited by 137
“The impact of the microbiome was strongly reinforced by clinical studies which demonstrated that anti-CTLA-4 toxicity can be influenced by gut bacterial composition [48,56].”
BackgroundThe biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Jia, X., Geng, L., Jiang, P., Xu, H., Nan, K., Yao, Y., Jiang, L., Sun, H., Qin, T., & Guo, H. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01749-x · Cited by 132
“CD177 and CEACAM1 Vafa Shahabi et al. analyzed the gene expression profiles of whole blood samples of melanoma patients treated with IPI and found that the neutrophil activation markers CD177 and CEACAM1 were highly expressed at baseline and postbaseline in patients with GI irAEs [28].”
BackgroundInfluentialFine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
Pitt, J. M., Vétizou, M., Waldschmitt, N., Kroemer, G., Chamaillard, M., Boneca, I. G., & Zitvogel, L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0448 · Cited by 128
Gut Microbiome and Response to Cardiovascular Drugs
Tuteja, S., & Ferguson, J. F. (2019) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002314 · Cited by 133
Heinzerling, L., Toni, E. D., Schett, G. A., Hundorfean, G., & Zimmer, L. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0119 · Cited by 156
Johnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118
Gao, Y., Xu, P., Sun, D., Jiang, Y., Lin, X.-L., Han, T., Yu, J., Sheng, C., Chen, H., Hong, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0605 · Cited by 116
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
“In a prospective study on immune-mediated colitis, bacteria of the Bacteroidetes phylum, which includes some of the most beneficial bacterial species, were enriched in colitis-resistant patients (81).”
BackgroundPharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response
Scher, J. U., Nayak, R. R., Úbeda, C., Turnbaugh, P. J., & Abramson, S. B. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0395-3 · Cited by 121
The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
Gong, J., Chehrazi‐Raffle, A., Placencio‐Hickok, V., Guan, M., Hendifar, A., & Salgia, R. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0225-x · Cited by 113
“Beyond associations between specific commensals and response (or lack of ) to checkpoint blockade, increased representation of baseline Bacteroidetes phylum (includes Bacteroides fragilis) in melanoma patients and intestinal reconstitution with Burkholderia cepacia in antibiotic-treated, tumorbearing mice have been sh…”
BackgroundThe immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications
Wang, X., Chen, L., Wei, J., Zheng, H., Zhou, N., Xu, X., Deng, X., Liu, T., & Zou, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02220-z · Cited by 146
Gut microbiota-mediated immunomodulation in tumor
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112
Toxicities Associated With PD-1/PD-L1 Blockade
Wang, D. Y., Johnson, D. B., & Davis, E. J. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000296 · Cited by 107
Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges
Jee, A., Sernoskie, S. C., & Uetrecht, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062954 · Cited by 127
“The microbiome does appear to affect the risk of immune checkpoint inhibitor-induced idiosyncratic reactions [15].”
BackgroundTsunoda, S. M., Gonzales, C., Jarmusch, A. K., Momper, J. D., & JOSEPH, D. R. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01032-y · Cited by 128
“In another mouse study, oral administration of Bifidobacterium species restored anti-PD-L1 antitumor activity resulting in dendritic cell maturation and increasing tumorspecific T-cell activity [88].”
Backgroundİmani, S., Farghadani, R., Roozitalab, G., Maghsoudloo, M., Emadi, M., Moradi, A., Abedi, B., & Kaboli, P. J. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03394-8 · Cited by 130
Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100
Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
Fessas, P., Possamai, L. A., Clark, J., Daniels, E., Gudd, C., Mullish, B. H., Alexander, J. L., & Pinato, D. J. (2020) · Immunology · doi:10.1111/imm.13141 · Cited by 105
Lo, B. C., Kryczek, I., Yu, J., Vatan, L., Caruso, R., Matsumoto, M., Sato, Y., Shaw, M. H., Inohara, N., Xie, Y., et al. (2024) · Science · doi:10.1126/science.adh8342 · Cited by 118
Metabolite and Microbiome Interplay in Cancer Immunotherapy
Johnson, C. H., Spilker, M. E., Goetz, L. H., Peterson, S. N., & Siuzdak, G. E. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0309 · Cited by 113
“In a prospective study of immune-mediated colitis, patients with greater bacteria from the Bacteroidetes phylum, particularly, Bacteroidaceae, Rikenellaceae, and Barnesiallaceae, were less likely to develop colitis (63).”
BackgroundClinical applications of gut microbiota in cancer biology
Wong, S. H., Kwong, T. N. Y., Wu, C., & Yu, J. Q. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.003 · Cited by 111
Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review
Szczyrek, M., Bitkowska, P., Chunowski, P., Czuchryta, P., Krawczyk, P. A., & Milanowski, J. (2021) · Nutrients · doi:10.3390/nu13072217 · Cited by 113
“Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium also improve anti-PD-1 response in metastatic melanoma patients [66,86,87].”
BackgroundAghamajidi, A., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14153563 · Cited by 110
Ševčíková, A., Izoldova, N., Števurková, V., Kasperova, B., Chovanec, M., Čierniková, S., & Mego, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010488 · Cited by 112
Deshpande, R. P., Sharma, S., & Watabe, K. (2020) · Cancers · doi:10.3390/cancers12102983 · Cited by 107
“For instance, the presence of bacteria from the Bacteroidetes phylum in stool samples of melanoma patients receiving anti-CTLA4 CPI, were less prone to treatment induced colitis [164].”
BackgroundPredictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Les, I., Martínez, M., Pérez-Francisco, I., Cabero, M., Teijeira, L., Arrazubi, V., Torrego, N., Campillo-Calatayud, A., Elejalde, I., Kochan, G., et al. (2023) · Cancers · doi:10.3390/cancers15051629 · Cited by 100
Species classifier choice is a key consideration when analysing low-complexity food microbiome data
Walsh, A. M., Crispie, F., O’Sullivan, O., Finnegan, L., Claesson, M. J., & Cotter, P. D. (2018) · Microbiome · doi:10.1186/s40168-018-0437-0 · Cited by 98
“Generally, the NextSeq or the HiSeq are preferred to the MiSeq for shotgun metagenomics, although there are several examples of the MiSeq also being used for this approach [20 – 22].”
Lee, D. J., Lee, H. J., Farmer, J. R., & Reynolds, K. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01530-2 · Cited by 108
Fecal Microbial Transplantation for Diseases Beyond Recurrent Clostridium Difficile Infection
D’Haens, G., & Jobin, C. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.04.053 · Cited by 108
“Dubin et al studied the intestinal microbiota of 34 patients with metastatic melanoma treated with ipilimumab and observed increased proportions of the Bacteriodetes phylum in patients who did not develop colitis (97).”
BackgroundSequencing-based analysis of microbiomes
Pinto, Y., & Bhatt, A. S. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00746-6 · Cited by 116
“For example, it helped demonstrate an association between specific gut microbial genes and metabolic pathways, such as vitamin B biosynthesis and polyamine transport, and the development of checkpoint blockade-induced colitis, a serious side effect of cancer immunotherapy 134 .”
Severe Gut Microbiota Dysbiosis Is Associated With Poor Growth in Patients With Short Bowel Syndrome
Piper, H. G., Fan, D., Coughlin, L. A., Ho, E. X., McDaniel, M. M., Channabasappa, N., Kim, J., Kim, M., Zhan, X., Xie, Y., et al. (2017) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607116658762 · Cited by 97
Pei, X., Heng, X., & Chu, W. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.105387 · Cited by 100
Oral delivery of bacteria: Basic principles and biomedical applications
Li, S., Jiang, W., Zheng, C., Shao, D., Liu, Y., Huang, S., Han, J., Ding, J., Tao, Y., & Li, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.011 · Cited by 97
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
Xie, J., Liu, M., Deng, X., Tang, Y., Zheng, S., Ou, X., Tang, H., Xie, X., Wu, M., & Zou, Y. (2024) · iMeta · doi:10.1002/imt2.156 · Cited by 108
“Two prospective studies of patients with metastatic melanoma reported that the overrepresentation of Bacteroidetes phylum in baseline stool samples of patients was related to the resistance to the onset of ipilimumab ‐ induced colitis [45, 58].”
BackgroundImmune Checkpoint Inhibitor-Associated Colitis and Hepatitis
Reddy, H. G., Schneider, B. J., & Tai, A. W. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/s41424-018-0049-9 · Cited by 96
Abu-Sbeih, H., Herrera, L. N., Tang, T., Altan, M., Chaftari, A.-M. P., Okhuysen, P. C., Jenq, R. R., & Wang, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0714-x · Cited by 93
“[12] They examined patients with melanoma treated with an anti-CTLA-4 regimen who underwent longitudinal follow-up.”
BackgroundImmunotherapy toxicity: identification and management
Gumusay, O., Callan, J., & Rugo, H. S. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06480-5 · Cited by 101
“Several studies have investigated the potential risk factors of IRAEs, including history of autoimmune disease, age, ethnicity, increased body mass index, genetic factors, and variations in the microbiologic composition of patients’ gastrointestinal flora [15].”
BackgroundThe Challenge for Development of Valuable Immuno-oncology Biomarkers
Mehnert, J. M., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D. E., Rubinstein, L., & Harris, L. N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3063 · Cited by 101
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Dougan, M., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 91
Secombe, K. R., Coller, J. K., Gibson, R. J., Wardill, H. R., & Bowen, J. M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31836 · Cited by 94
“There is significant heterogeneity in the microbiome and in immune function, and as such, this emergent data represents a chance to personalise cancer treatment, and allow the identification of patients at risk of severe symptoms.(10,11) However Key words: microbiome, chemotherapy, gastrointestinal tract, innate immun…”
BackgroundInamura, K., Hamada, T., Bullman, S., Ugai, T., Yachida, S., & Ogino, S. (2022) · Gut · doi:10.1136/gutjnl-2022-327209 · Cited by 100
Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment
Pouncey, A. L., Scott, A. J., Alexander, J. L., Marchesi, J. R., & Kinross, J. K. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.868 · Cited by 114
“Administration of Bacteriodales has subsequently been shown to reduce CTLA-4 blockade induced colitis in an antibiotic-treated mouse model [4, 35].”
BackgroundEffects of microbiota on anticancer drugs: Current knowledge and potential applications
Huang, J., Liu, W., Kang, W., He, Y., Yang, R., Mou, X., & Zhao, W. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104197 · Cited by 103
The human microbiome and cancer: a diagnostic and therapeutic perspective
Kandalai, S., Li, H., Zhang, N., Peng, H., & Zheng, Q. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2240084 · Cited by 101
“Patients that were colitis-free following anti-CTLA-4 immunotherapy had a higher abundance of bacteria belonging to the families Bacteroidaceae, Rikenellaceae and Barnesiellaceae, with a model trained on these reads able to categorize patients with a sensitivity of 70% and specificity of 100%.(122) Another study analy…”
BackgroundMicrobiome epidemiology and association studies in human health
VanEvery, H., Franzosa, E. A., Nguyen, L. H., & Huttenhower, C. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00529-x · Cited by 94
Self-citationPerillo, F., Amoroso, C., Strati, F., Giuffrè, M. R., Díaz‐Basabe, A., Lattanzi, G., & Facciotti, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155389 · Cited by 91
Ibis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 98
Thomas, M. F., Slowikowski, K., Manakongtreecheep, K., Sen, P., Samanta, N., Tantivit, J., Nasrallah, M., Zubiri, L., Smith, N. P., Tirard, A. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02895-x · Cited by 104
“We speculate that the intestinal microbial environment, which is correlated with ICI anti-tumor immune responses and irColitis 67,68 , may be an important driver of the CD8 T cell Th17 gene program. irColitis was marked by the expansion of recirculating ITGB2 Hi G-ZMK Hi and ITGB2 Hi CX3CR1 Hi…”
State of the Art in the Culture of the Human Microbiota: New Interests and Strategies
Alou, M. T., Naud, S., Khelaifia, S., Bonnet, M., Lagier, J., & Raoult, D. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00129-19 · Cited by 100
Lin, A., Xiong, M., Jiang, A., Huang, L., Wong, H. Z. H., Feng, S., Zhang, C., Yu, H., Chen, L., Chi, H., et al. (2025) · iMeta · doi:10.1002/imt2.70070 · Cited by 108
Wardill, H. R., Secombe, K. R., Bryant, R. V., Hazenberg, M. D., & Costello, S. P. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.070 · Cited by 92
“Certain bacterial signatures have been shown to associate with differential responses to immunotherapies [42,43], both in terms of treatment efficacy and toxicity.”
BackgroundThe Clinical Link between Human Intestinal Microbiota and Systemic Cancer Therapy
Aarnoutse, R., Ziemons, J., Penders, J., Rensen, S. S., de Vos-Geelen, J., & Smidt, M. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174145 · Cited by 83
“…prausnitzii ↑ Holdemania filiformis ↑ Bacteroides thetaiotamicron n = 13 Pembrolizumab Metagenomic shotgunsequencing Response (n = 6) ↑ Dorea formicigenerans Dubin et al. (2016), [29] Metastatic Melanoma n = 34 Ipilimumab 16S rRNA gene sequencing Colitis free ↑ Bacteroidaceae ↑ Bacteroides ↑…”
BackgroundInfluentialPhạm, V. H., Abbas, W., Huang, J., He, Q., Zhen, W., Guo, Y., & Wang, Z. (2021) · Poultry Science · doi:10.1016/j.psj.2021.101563 · Cited by 94
“Faecalibacterium are related health-related bacteria, which are correlated with reduction in the expansion of regulatory T-cell and stimulate the production of anti-inflammatory cytokines, exhibit anti-inflammatory properties in the gut (Shaufi et al., 2015; Chang et al., 2016; Dubin et al., 2016).”
BackgroundImmunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition
Siefker-Radtke, A. O., & Curti, B. D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.190 · Cited by 89
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors
Zhong, L., Wu, Q., Chen, F., Liu, J., & Xie, X. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02803-5 · Cited by 89
Brown, H. M., & Esterházy, D. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00420-8 · Cited by 95
“Intriguingly, the microbial composition appears to play a role in whether this happens at all and in what severity, suggesting that engineering a protective microbial community to counter this periling side effect may be a way to reduce the risk.(126,127) However, on the flip side, the efficacy of anti CTLA4 treatment…”
BackgroundBazin, T., Hooks, K. B., Barnetche, T., Truchetet, M., Enaud, R., Richez, C., Dougados, M., Hubert, C., Barré, A., Nikolski, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23571-4 · Cited by 89
Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review
Collins, M., Soularue, É., Marthey, L., & Carbonnel, F. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.033 · Cited by 93
Metadata
- Authors
- Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., Pamer, E. G., & Wolchok, J. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Broad Institute (US)
- Corresponding author
- Pamer, Eric G.
- Wolchok, Jedd D.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-02-02
- Volume
- 7
- Issue
- 1
- Pages
- 10391-10391
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4740747
- OpenAlex
- W2275606382
- Cited by
- 987
- References
- 40
- Citations by year
- 2026: 56 · 2025: 76 · 2024: 83 · 2023: 117 · 2022: 145 · 2021: 128 · 2020: 131 · 2019: 112 · 2018: 71 · 2017: 48 · 2016: 19
- FWCI
- 43.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bristol-Myers Squibb
- Memorial Sloan-Kettering Cancer Center (P30 CA008748)
- Tow Foundation
- National Institutes of Health
- Weill Cornell Medical College
- National Cancer Institute (P30CA008748)
- National Institute of General Medical Sciences (T32GM007739)
- National Institute of Allergy and Infectious Diseases (R01 AI42135, R01AI042135)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- ipilimumab, CTLA-4, metastatic melanoma, gut microbiota, Bacteroidetes, immune-related adverse events, cancer immunotherapy, polyamine transport, B vitamin biosynthesis, biomarkers, inflammatory bowel disease
- MeSH terms
- Gastrointestinal Microbiome, Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Bacteroidaceae, Colitis, Female, Humans, Male, Melanoma, Middle Aged, Prospective Studies, Risk Factors, RNA, Ribosomal, 16S, Skin Neoplasms, Sequence Analysis, RNA, Bacteroidetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.